Promising Developments in Voyager Therapeutics’ Alzheimer’s Programs Highlight Potential of Dual Tau-Targeted Therapies

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Voyager Therapeutics (VYGR – Research Report), retaining the price target of $30.00.

Patrick Trucchio’s rating is based on promising developments in Voyager Therapeutics’ Alzheimer’s programs. The company’s presentations at the Alzheimer’s & Parkinson’s Disease conference showcased significant preclinical data for their dual approach to tau-targeted therapy, involving the anti-tau antibody VY7523 and tau silencing gene therapy VY1706. These findings highlight VY7523’s ability to selectively target pathological tau and inhibit its spread, while VY1706 demonstrated effective knockdown of tau mRNA and protein in key brain regions.
Trucchio is optimistic about the potential of Voyager’s TRACER capsid platform for CNS delivery and the complementary mechanisms of action of their therapies. The upcoming catalysts, such as tau PET data from the VY7523 study and an IND filing for VY1706, are expected to unlock significant value. Additionally, the data from competing anti-tau programs provide positive predictive value for VY7523, supporting its continued development and potential patient stratification strategies.

According to TipRanks, Trucchio is an analyst with an average return of -10.4% and a 25.51% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Altimmune, and Milestone Pharmaceuticals.